Close Menu

data mining

With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.

Japanese software giant NEC invests in AI-centric software company BostonGene to advance immuno-oncology and other targeted cancer treatments.

The agency hopes to gain data on the efficacy of BRAF targeted drugs used in sequence, and how physicians implement treatments compared to how the drugs are labelled.